Novo’s CagriSema drives more than 20% weight loss at lower doses
As Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed investors a couple of years ago.
comments(0)
5-min edit window · permanent after that